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Abstract 
Human genetic research has succeeded in definitively identifying multiple genetic variants 
associated with risk for nicotine dependence and heavy smoking. To build on these advances and 
aid in reducing the prevalence of smoking and its consequent health harms, the next frontier is to 
identify genetic predictors of successful smoking cessation and also of the efficacy of smoking 
cessation treatments ("pharmacogenomics").  More broadly, additional biomarkers that can be 
quantified from biosamples also promise to aid "Precision Medicine" and the personalization of 
treatment, both pharmacological and behavioral. To motivate ongoing and future efforts, here we 
review several compelling genetic and biomarker findings related to smoking cessation and 
treatment. These include genetic variants in the nicotinic receptor subunit gene CHRNA5, 
variants in the nicotine metabolism gene CYP2A6, and the nicotine metabolite ratio. We also 
summarize reports of epigenetic changes related to smoking behavior. The results to date 
demonstrate the value and utility of data generated from biosamples in clinical treatment trial 
settings. This paper cross-references a companion paper in this issue that provides practical 
guidance on how to incorporate biosample collection into a planned clinical trial and discusses 
avenues for harmonizing data and fostering consortium-based, collaborative research on the 
pharmacogenomics of smoking cessation. 
 
 
 
Implications 
Evidence is emerging that certain genotypes and biomarkers are associated with smoking 
cessation success and efficacy of smoking cessation treatments. We review key findings that 
open potential avenues for personalizing smoking cessation treatment according to an 
individual's genetic or metabolic profile. These results provide important incentive for smoking 
cessation researchers to collect biosamples and perform genotyping in research studies and 
clinical trials. 
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1. Introduction 
Cigarette smoking remains a leading preventable cause of global morbidity and mortality 1-
2.Addressing this problem requires a two-pronged strategy both to prevent individuals from 
initiating cigarette use and to assist current smokers in the process of quitting. Despite substantial 
educational and policy-related initiatives to discourage smoking, extrapolation from recent trends 
suggests there are likely to be more than a billion smokers worldwide by 2025 3. Thus, for the 
foreseeable future, smoking cessation treatments will remain an indispensable component of 
tobacco control efforts. Although a number of effective smoking cessation interventions have 
been developed and disseminated, clinical trials of evidence-based treatments typically find that 
60% or more of treated smokers relapse within 5-6 months 4. Research that advances our 
understanding of the basic neurobiological determinants of smoking and relapse has potential to 
accelerate progress in smoking cessation treatment.  
 Recent characterization of the human genome, combined with advances in genotyping 
technology, have led to an explosion of new knowledge concerning the genetics of complex 
diseases 5. Nicotine and tobacco research has made substantial contributions to this emerging 
literature, producing some of the largest replicable effects of genotypes on disease risk or related 
traits in neuropsychiatric genetics 6-9. One exciting implication of this work is the possibility of 
new opportunities for precision medicine for smoking cessation 10-11, for which multiple 
treatments are available, both pharmacological and behavioral. Existing studies indicate that 
various biomarkers, including genotypes, predict responses to smoking cessation 
pharmacotherapies 12-13. Importantly, genotypes are also associated with naturalistic cessation 
and the course of smoking-related disease, highlighting their clinical impact 14. Ideally, as 
pharmacogenomic evidence accumulates and as the costs of genetic assays decrease, it will 
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become possible to tailor treatment strategies to individuals in routine clinical practice, 
improving treatment efficacy and minimizing adverse effects. Basic research into the genetics of 
smoking may also reveal new insights into the pathophysiology of nicotine dependence, 
identifying novel treatment targets.  
 Even with these successes, substantial challenges must be overcome to realize the clinical 
promise of this swiftly growing body of genetic research. One clear lesson from existing studies 
is that the effect sizes of individual common genetic variants on common, complex phenotypes 
are small in absolute magnitude, often accounting for ~1% of phenotypic variance in measures 
such as cigarettes per day or tobacco dependence (e.g. 15-18). Detecting such small, but 
biologically meaningful, effects is made more complicated by the need to apply stringent 
statistical corrections for multiple testing when many variants are examined simultaneously. 
Owing to concerns about possible false positives and publication bias, genetic research places a 
premium on independent replication and meta-analysis 19-21. Finally, assessment of rare variants 
may be necessary to fully characterize genetic contributions to smoking and nicotine dependence 
15, 22-25.  
 These considerations indicate that the way forward requires the use of very large samples, 
probably numbering in the tens of thousands of individuals, especially if the phenotypes are 
based on self-report. Such large-scale studies rely on collaboration across many independent 
investigators and have been very productive in human genetics generally 26.  Another strategy to 
increase statistical power is to use biomarkers 27 that are relevant for smoking, such as cotinine 
28-30,  exhaled carbon monoxide 18, or the nicotine metabolite ratio 31-36. For these biomarkers, the 
proportion of variance accounted for by genetic loci is several fold greater than for standard 
smoking measures, and association studies find multiple genome-wide significant findings with 
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much smaller sample sizes. Epigenetic studies also have the potential to leverage modest sample 
sizes, as large effect sizes have been reported for the association between levels of DNA 
methylation (a commonly studied epigenetic process) and smoking-related phenotypes. 
Ultimately, to establish and extend the clinical utility of genetic research for smoking cessation, 
genetic variants and other biomarkers must be assayed and analyzed together with clinically 
relevant and detailed phenotypic data from the same individuals. Important traits include relapse 
status, time to various behavioral and clinical milestones (including comorbidities and 
consequent disease), adherence to and adverse effects from pharmacotherapies, and potential 
mediators of treatment effects (e.g., withdrawal symptoms, craving, lapse antecedents and 
consequences). 
 Clearly, much can be gained by moving beyond a traditional model of clinical research 
relying on small teams of investigators working independently. Progress will require a concerted, 
“big science” effort. This article is one of a pair of review papers produced through collaboration 
between the Genetics Network and the Treatment Network of the Society for Research on 
Nicotine and Tobacco (SRNT). The overarching aim of these reviews is to facilitate this big 
science approach by encouraging clinical researchers to routinely collect and bank biospecimens, 
even when they have no immediate plans to analyze the samples or link biomarkers to clinical 
outcomes. To the extent this becomes a standard practice, nicotine and tobacco researchers will 
create a reservoir of genetically informative clinical data that can be tapped to speed the pace of 
scientific discovery and foster the development of precision medicine approaches. Future 
collaborative analyses of this collective resource will be expedited if investigators work together 
and communicate to determine scientific priorities and promote consistent phenotypic 
assessments to address them. 
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 To set the stage for this kind of effort, the current article reviews selected examples of 
how data generated from biosamples - specifically genotypes, metabolite measurements, and 
epigenetic profiles - have been valuable for tobacco research, including evidence concerning the 
moderation of treatment effects by genotype. The first sections present the two most well-
established genetic findings for smoking behavior to date, the CHRNA5 cholinergic nicotinic 
receptor subunit gene and the CYP2A6 nicotine metabolism gene. An additional section presents 
epigenetic findings relevant for smoking and cessation research.  A companion article 37 offers 
practical information on how to incorporate biosample collection into a planned clinical trial, 
considers issues surrounding data curation and sharing, and looks forward to consortium-based 
approaches for pooling and analyzing the data. Table 1 introduces a glossary of genetics and 
genomics terms that will be used throughout this review paper and also the companion article 37.  
Table 2 summarizes key genetic findings for CHRNA5 and CYP2A6 that this review will 
highlight. 
2. Genetic variants in CHRNA5, the 5 cholinergic nicotinic receptor subunit gene 
CHRNA5 and smoking:  
 Genetic variants in CHRNA5, the gene encoding the 5 cholinergic nicotinic receptor 
subunit, have come to prominence for their associations with smoking traits including nicotine 
dependence 38, 56, smoking quantity and heaviness, e.g. cigarettes per day 16, 40-41, 43, and 
biomarkers of smoking such as cotinine 28-30, total nicotine equivalents 57, and carbon monoxide 
18. In particular, studies of European-ancestry smokers have identified and replicated the non-
synonymous single nucleotide polymorphism (SNP) rs16969968, which causes an amino acid 
change from aspartic acid to asparagine that alters in vitro function of CHRNA5 58. Furthermore, 
this variant and its correlated proxies are associated with smoking-related diseases such as lung 
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cancer 38, 45, 59 and chronic obstructive pulmonary disease 46-47. This CHRNA5 region also harbors 
multiple independently associated loci; for example, a distinct group of variants, including 
rs880395 and rs588765, are associated with smoking when rs16969968 is included as a 
covariate, and are also associated with CHRNA5 mRNA levels (gene expression) in brain 60-62. 
Other variants in the surrounding genes (e.g. IREB2, and additional nicotinic receptor subunit 
genes CHRNA3 and CHRNB4) are highly correlated (in linkage disequilibrium) with these 
CHRNA5 variants and thus also show associations with smoking. 
 Less work has been performed in non European-ancestry populations. Nevertheless, 
CHRNA5 variants are associated with smoking behaviors in large studies of African-ancestry and 
Asian-ancestry smokers 42, 63. A genome-wide meta-analysis of 32,389 African-ancestry 
participants, including 15,547 ever-smokers, observed genome-wide significant association 
between cigarettes per day and rs2036527, a SNP in the distal enhancer region of CHRNA5 42. 
Though this SNP does not confer an amino acid change, in African-ancestry populations it tags 
the CHRNA5-expression-associated haplotype 60-62. Another meta-analysis targeted CHRNA5 
variants in smokers of African (N=10,912), Asian (N=6,889), and European (N=14,786) ancestry 
63; all three ancestry groups showed consistent association of the non-synonymous SNP 
rs16969968 with heavy smoking, despite considerable allele frequency differences, ranging from 
42% in European-ancestry samples to 7% in African Americans and 3% in Asians. Other non-
European populations with differing haplotype structure or low frequency for rs16969968 may 
show association with the CHRNA5/A3/B4 region though not necessarily this variant 51, 57, 64. 
 These genetic associations with nicotine dependence and related smoking behaviors have 
motivated several studies of the utility of CHRNA5 variants to predict efficacy of smoking 
cessation treatment in randomized clinical trials. The results, outlined below, demonstrate both 
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the potential of genetic information to enable personalized treatment, and also the importance of 
careful interpretation that accounts for study design and potential environmental effects.   
CHRNA5 and smoking cessation treatment  
 Evidence from multiple treatment trials indicates that the CHRNA5 variants involved in 
nicotine dependence risk can distinguish between smokers who are likely to respond strongly to 
pharmacologic treatment and those who are unlikely to benefit 49-50, 65-68. 
 We focus here on evidence that the functional variant rs16969968 is associated with 
treatment response. In 1,075 European-American smokers in a randomized, placebo-controlled 
clinical trial, genetic analyses compared high- and low-risk haplotypes for nicotine dependence, 
defined by two SNPs: rs16969968 (the amino acid change D398N) and rs880395 (associated 
with CHRNA5 mRNA expression changes) 49. Biochemically confirmed 7-day point prevalent 
abstinence at end-of-treatment was analyzed as the cessation outcome. All participants received 
behavioral counseling and were randomized to placebo or active treatment (nicotine replacement 
therapy (NRT), buproprion, and combination of both). Results showed a significant interaction 
between treatment and haplotype  (2 = 8.97, df=2, omnibus p = 0.02). Specifically, individuals 
with the high-risk haplotype had the lowest abstinence rate when treated with placebo plus 
counseling; however, adding pharmacologic treatment for smoking cessation significantly 
increased the likelihood of smoking cessation back to levels comparable to the low-risk 
haplotype group. In contrast, those with the low-risk haplotype received little effect from 
pharmacologic treatment for smoking cessation; they quit just as successfully with placebo plus 
counseling.  These results translate to a dramatic difference between the two genetic profiles in 
the number needed to treat (NNT), the number of people who must receive treatment for one 
person to benefit. The NNT was 4 for smokers with the high-risk profile, versus over 1000 for 
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smokers with the low-risk profile 69-70.  Moreover, the high-risk haplotype is quite common, with 
a frequency of 21% in this European-American sample, translating to meaningful impact on a 
population level. 
 The interaction between CHRNA5 genetic status and pharmacological treatment was 
confirmed in a combined analysis of 2,633 European-ancestry smokers from eight randomized 
clinical trials 50, including data from the trial in Chen et al. 49. As before, CHRNA5 SNPs 
representing the amino acid change and the mRNA expression change were highlighted. In 
particular, at the available proxy SNPs selected for analysis, the minor alleles for the amino acid 
change and the expression change were significantly associated with reduced six month 7-day 
point prevalent abstinence in the placebo group, and with increased abstinence in participants 
randomized to nicotine replacement therapy. The minor allele for the amino acid change was 
also associated with significantly reduced abstinence in the placebo group at end of treatment. 
 In non European-ancestry smokers, there is also evidence that CHRNA5 is associated 
with treatment response. Multiple candidate SNPs in the CHRNA5-A3-B4 region were analyzed 
for association with two randomized, placebo controlled trials of African-Americans for smoking 
cessation 66. The functional SNP rs16969968 had low allele frequency and did not show 
consistent association; however the A allele of rs2036527, which in African-ancestry cohorts is 
associated with cigarettes per day 42, was associated with lower abstinence with active 
pharmacotherapy during treatment and at end of treatment for nicotine gum, and when analyzing 
pooled data from the nicotine gum and bupropion trials 66.  
 However, some studies of CHRNA5 in treatment trials have been less conclusive. We 
describe these next, and discuss how these varied reports highlight the importance of considering 
study design and potential environmental factors when interpreting results.  
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  A recent meta-analysis of four clinical trials found no evidence that rs16969968 or its 
proxy rs1051730 increased smoking cessation in smokers receiving nicotine replacement therapy 
71. Although this result may at first appear to argue against a role for CHRNA5 in treatment 
response, in fact it is consistent with the prior evidence that CHRNA5 variants interact with 
treatment to significantly affect cessation. To see such an interaction, it is necessary to analyze 
both the non-pharmacologically treated (placebo) group and the treated group: carriers of the risk 
variants quit poorly on placebo, but those treated by NRT were "rescued" to attain cessation rates 
comparable to the low-risk genetic group. Thus a comparison of genetic status only in 
pharmacologically treated smokers, as in 71, is not designed to inform about this interaction.  
 In a separate, placebo-controlled clinical trial of 654 European-ancestry smokers, 
CHRNA5 genotype by treatment interactions were specifically analyzed and found to be not 
statistically significant 72. This suggests that the effect may not be robust over different trials or 
populations of smokers. Still, the direction of effect trended in the expected direction, with lower 
cessation rates in placebo-treated, genetically high-risk smokers, but no statistical evidence of 
rescue by NRT.   
 The varied results highlight the need to improve statistical power via increased sample 
sizes, and to include understudied racial groups and account for diverse population histories. One 
challenge is that individual SNP effects discovered in large samples may be modest; however 
such findings are still valuable because they implicate specific genes and biological pathways 
and can improve polygenic score estimates. Also important is the consideration of non-genetic 
(environmental) factors that are well-established predictors of smoking cessation, as these may 
be involved in differences seen across trials.  The strong CHRNA5 effect reported in 49 was 
observed in a population of smokers who displayed strong motivation to quit. Similarly, a 
Page 11 of 33 
 
naturalistic study of cessation in pregnant women smokers, who are generally expected to have 
strong motivation to quit, found significant association between CHRNA5 risk genotype and 
reduced abstinence 48. It is plausible that a setting of strong motivation or pressure to quit may 
highlight contrasts between genetically high-risk and low-risk smokers, thus more clearly 
manifesting that genetically high-risk smokers have reduced ability to quit without 
pharmacologic treatment. It is this reduced ability that underlies the significant genotype-by-
treatment interaction in 49 and 50. Other important factors may include partner smoking 73, 
treatment adherence 74, and adverse effects 75. Overall, assessment of motivation and other 
modifying factors in clinical trials will be valuable to fully characterize the role of genetics in 
treatment response and cessation. 
 In summary, significant CHRNA5 effects on treatment efficacy have been observed in 
several, though not all, studies. Genetic analyses of additional, well-phenotyped treatment trials 
that include placebo treatment arms will be crucial to establishing whether this promising 
biological predictor ultimately will have clinical value for smokers seeking to quit. The current 
evidence provides strong motivation for further biosample collection in clinical trials for genetic 
research. Future studies in larger samples, as well as collaboration across studies, are important 
to increase power to examine specific medications for potential differences in effect.  
 
3. CYP2A6 and nicotine metabolism biomarkers 
 Nicotine is the main addictive component in tobacco and to a large extent responsible for 
the maintenance of smoking, and individuals vary in their nicotine clearance rates 76-77. Thus 
biomarkers of nicotine metabolism - including genotypes at nicotine metabolism genes and direct 
measures of metabolite levels in blood, plasma, or urine - are valuable for the study of smoking 
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behavior. Unlike cotinine and carbon monoxide, which are used as biomarkers of smoking 
behavior such as amount smoked, and which demonstrate associations with CHRNA5 18, 28-30, 
biomarkers of nicotine metabolism focus on representing variability in metabolism, which 
contributes in specific ways to smoking behavior. 
CYP2A6 and smoking 
The CYP2A6 gene on chromosome 19 encodes the enzyme involved in metabolizing nicotine 
and also its major metabolite, cotinine 78-79.  CYP2A6 variants, and neighboring variants in 
EGLN2, a gene associated with response to hypoxia 80, are among the consistent genome-wide 
significant signals associated with cigarette consumption 16, 40, 51. EGLN2 variation has recently 
been shown to be associated with cigarette consumption independently of CYP2A6 variation, and 
also associated with nicotine dependence measures and with smoking efficiency (the ratio of 
carbon monoxide over cigarette consumption), though not with nicotine metabolism 81.  
CYP2A6 and biomarkers of CYP2A6 activity 
 CYP2A6 enzyme activity can be represented by the ratio of plasma or salivary trans-3’-
hydroxycotinine/cotinine or urinary trans-3’-hydroxycotinine plus trans-3’-hydroxycotinine 
glucuronide/cotinine (3HC/COT), a biomarker known as the nicotine metabolite ratio (NMR) 31. 
Higher NMR values indicate faster nicotine metabolism.  
 NMR is influenced by individual genetic variation and also other factors beyond CYP2A6 
genotype, such as hormones. From twin modeling, the proportion of variation of NMR 
attributable to additive genetics is estimated to be ~67-81% and 47% for NMR measured from 
plasma and urine, respectively 32, 82, and is reduced to ~49% and 42% upon adjustment for 
genotyped CYP2A6 variants 82. At the same time, the influences of environmental and 
demographic variables explain only 8% of the variance in NMR 83. These estimates suggest that 
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NMR is influenced by these CYP2A6 alleles and also by additional heritable variation. Indeed, a 
candidate gene study of drug metabolizing enzyme and transporter (DMET) gene variation 
confirmed a major role for CYP2A6 variation in nicotine metabolism, attaining genome-wide 
significant association of specific CYP2A6 variants with NMR 33. Furthermore, recent genome-
wide studies of NMR have identified genome-wide significant associations with CYP2A6 
variants 32, 34, 52. In particular, all three studies identified a CYP2A6 intervening sequence four 
(IVS4) variant, rs56113850, that is associated with reduced NMR in European ancestry 
individuals. The first of these GWAS meta-analyses used cotinine-verified current smokers (N = 
1,518) from multiple Finnish cohorts 32; methylation analyses were also conducted, and are 
described in the next section on epigenetics. Of the hundreds of genome-wide significant signals 
discovered in the region of chromosome 19q13.2, the most significant was the CYP2A6 IVS4 
variant rs56113850 (p=5.8E-86). Conditional analyses identified three additional independent 
genome-wide significant associations in the region. The top three SNPs account for 31% of 
NMR variance in these Finnish cohorts. The IVS4 SNP was later replicated in a separate GWAS 
meta-analysis of the laboratory-based NMR in 49 African, 51 Asian, and 212 European ancestry 
individuals 34. The most statistically significant results were a SNP proximal to CYP2A6 
(rs12459249, p = 2.5E-18), and the IVS4 SNP (rs56113850, p = 6.6E-18); another region in the 
CYP2A6-CYP2A7 intergenic region yielded two signals with p <3E-10. Bioinformatic analyses 
of rs56113850 further connected this variant to reduced transcription in liver and lung and 
reduction of incorporation of exon 5 of CYP2A6 in liver 34. Further replication of rs56113850 
was observed in a third GWAS of  2,239 current smokers of African American, Native 
Hawaiian, White, Latino, and Japanese American ethnicity; this IVS4 SNP was the most 
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significant signal in the multi-ethnic GWAS and the only SNP that was genome-wide significant 
in each of the five ethnic groups with sample sizes ranging from 311 to 674 participants. 
 An alternative biomarker of CYP2A6 activity directly uses genotypes at variants at 
CYP2A6 in a regression model to predict the ratio of cotinine over the sum of nicotine and 
cotinine [COT/(NIC+COT)]. This genotype-based activity metric accounted for 73% of the 
variance in COT/(NIC+COT) 30 minutes after oral administration of labeled compound, and 
44% of the variance in NMR at six hours after oral nicotine administration, in European-
American subjects 84. The regression model derived from those data provides a biomarker of 
CYP2A6 activity that can be calculated from seven CYP2A6 variants that are reported to be 
relatively common in Europeans, and does not require direct nicotine metabolite measurements. 
 This genotype-based metric was subsequently studied for its associations with smoking 
behaviors in a distinct sample of smokers. In both European-American and African-American 
smokers, the metric was associated with cigarettes per day 53.  
Biomarkers of CYP2A6 activity and smoking cessation treatment:  
 We have outlined how CYP2A6 activity can be represented by the metabolite-based 
NMR and by an alternative metric based on CYP2A6 genotypes. Both these biomarkers have 
shown associations with efficacy of smoking cessation treatment in clinical treatment trials, 
indicating their potential as tools to personalize treatment. 
 Several studies have evaluated NMR and efficacy of nicotine replacement therapy (NRT) 
and found that low NMR (indicating slower metabolism) corresponds to greater nicotine patch 
effectiveness. First, an open-label, randomized, intention to treat strategy compared transdermal 
nicotine vs. nicotine nasal spray in 480 smokers who all received behavioral therapy 85.  The 
hypothesis was that higher NMR would be associated with lower cessation success rates with 
Page 15 of 33 
 
NRT, measured via the primary outcome of prolonged abstinence at the end of treatment and at 6 
months’ follow-up. The effect of pre-treatment NMR on abstinence was tested in the total 
sample and in each treatment group controlling for pre-treatment nicotine dependence 
(Fagerström score), Body Mass Index, race, and sex.  NMR was associated with the effectiveness 
of transdermal nicotine: among smokers treated with transdermal nicotine, low NMR 
corresponded to greater abstinence. Additionally, higher NMR predicted lower nicotine 
concentrations and more severe cigarette cravings after one week of treatment.  There was no 
association of NMR and nicotine nasal spray, which the authors speculated could be related to 
pharmacodynamic differences. This correspondence of low NMR to greater nicotine patch 
effectiveness has been replicated in other clinical trials 54, 86 and in a community-based trial 87. In 
African-American smokers, an overall association of low NMR with greater quit success was 
observed in both the NRT arm and the placebo arm 88. 
 The association of NMR with smoking cessation was furthermore evaluated in a 
prospective, biomarker-stratified clinical trial comparing transdermal nicotine vs. varenicline 35.  
In this 11-week, multicenter, randomized, placebo-controlled, double-blinded, intention to treat 
trial, motivated smokers were assigned to placebo (placebo pill/placebo patch), NRT (active 
patch/placebo pill), or varenicline (active pill/placebo patch).  All subjects also received 
behavioral counseling.  The primary endpoint was biochemically verified 7-day point prevalence 
abstinence at the end of treatment (EOT).  The primary hypothesis was an NMR-by-treatment 
interaction at EOT.  Of the 1246 participants, 662 were characterized as slow metabolizers of 
nicotine (NMR <0.31) and 584 were considered normal/rapid nicotine metabolizers (NMR > 
0.31).  At EOT and at six months, varenicline was significantly more effective than transdermal 
nicotine in normal (p-values of 0.001 and 0.03) but not in slow (p-values of 0.56 and 0.51) 
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metabolizers. In a longitudinal model incorporating EOT, 6-month, and 12-month time points, 
the NMR-by-treatment interaction was significant [ratio of odds ratios = 1.96 (95% CI 1.11 – 
3.46) p = 0.02]. In slow metabolizers compared to normal metabolizers, an NMR-by-treatment 
interaction found greater side effect severity from varenicline vs. placebo [β = -1.06 (95% CI -
2.08 to -0.03), p =0.044].  Thus for normal metabolizers, varenicline was found to be superior to 
transdermal nicotine, corresponding to an NNT in this group of 4.9 for varenicline versus 26.0 
for nicotine patch. Transdermal nicotine was equivalent to varenicline in slow metabolizers, and 
slow metabolizers were significantly more likely to report side effects from varenicline 
compared to placebo.   
 The genotype-based metric developed in 53, 84 is an alternative biomarker that shows 
association with treatment efficacy. This metric was used to classify 709 European-ancestry 
participants as slow (lowest quartile of the metric) versus normal (the remaining quartiles) 
metabolizers, in a randomized trial of placebo, active (nicotine replacement therapy, bupropion) 
and combined active therapies 89 55. Among smokers receiving placebo, slow metabolizers were 
less likely to relapse at end of treatment compared to normal metabolizers (hazard ratio 
(HR)=0.40, p=0.013). In addition, Chen et al identified significant effects of NRT in reducing 
smoking relapse among fast metabolizers (HR=0.50, p=4.4E-6), but not among normal 
metabolizers (HR=0.93, p=0.75). In contrast, there were no significant differences in treatment 
effect by metabolism metric among those receiving bupropion. The differences in relapse rate by 
pharmacotherapy and genotype-based nicotine metabolism metric generated a significant 
interaction in the entire sample (HR=2.55, p=0.016). For those randomized to NRT versus 
placebo, the number needed to treat (NNT) differed significantly by nicotine metabolism status 
(2.9 for normal metabolizers and >1,000 for slow metabolizers). 
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 Together, the findings outlined above indicate that further work to develop, compare, and 
test biomarkers of nicotine metabolism has the potential to pave the way for personalized 
smoking cessation treatment. One priority - and opportunity - is to more comprehensively 
address how nicotine metabolism speed impacts the efficacy of NRT, before clinical translation. 
As reviewed above, multiple clinical trials that used NMR to define metabolism speed found that 
slow metabolizers respond to NRT, with greater benefit than normal/fast metabolizers 35, 54, 85-86. 
In contrast, a clinical trial that used a CYP2A6 genotype-based metric to characterize nicotine 
metabolism speed found that slow metabolizers do not benefit from NRT compared to placebo, 
while normal/fast metabolizers benefit greatly 55. These contrasting results may be due to a 
combination of several factors, including differences in the trial populations and in the way 
metabolism speed was measured. Reconciling these results should be possible with further 
biospecimen collection and genotyping in clinical trials that will allow comparison of these 
metabolite-based and genotype-based measures in the same clinical trial subjects. Finally, large 
trials involving non-European-ancestry smokers are needed: in African-Americans, analyses of 
CHRNA5 66 and nicotine metabolism 88 indicate that both influence cessation success, but further 
work is needed to understand the direction of effect and the role of pharmacologic treatment.  
 
4. Epigenetics  
 Epigenetic processes define non-genetic modifications to the DNA that can alter gene 
regulation. The most commonly studied epigenetic process is DNA methylation, in which methyl 
groups attach to Cytosine-Guanine (CpG) dinucleotides in the DNA sequence with subsequent 
impact on gene expression 90. With the advent of genome-wide arrays for DNA methylation 
measurement, it is possible to measure DNA methylation at single CpG sites throughout the 
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genome, analogously to genome-wide SNP arrays 91. For the majority of population-based 
studies to date, DNA from peripheral blood cells has been the sample source used to measure 
DNA methylation, as other tissues are less readily accessible in large samples. The widespread 
use of this method has enabled replication efforts of findings in the field. Here we describe DNA 
methylation findings relevant to smoking. In particular, methylation levels at certain loci have 
been shown to be responsive to exposure to tobacco smoke, suggesting potential for application 
as markers of smoking status, including successful cessation. 
Summary of epigenome-wide association studies for smoking: 
Current tobacco smoking is robustly associated with DNA methylation in blood at a distinct set 
of loci across the genome. These findings have been comprehensively replicated in a number of 
population studies, using arrays 92-96 and also other laboratory technologies 92, 95-96. A recent 
systematic review indicates that smoking-related methylation signatures may provide 
informative biomarkers not only for current smoking but also life-time exposure 97. Of almost 
200 replicated methylation sites associated with smoking exposure to date, the most well-known 
locus is AHRR (Aryl-Hydrocarbon Receptor Repressor). A CpG site annotated as cg05575921 on 
the Illumina Infinium HumanMethylation450 BeadChip (to date the most commonly used 
platform for this type of analysis, interrogating over 485,000 methylation sites), located in an 
intronic region of AHRR, is the site most commonly associated with smoking in both adults 96, 98-
101 and adolescents 102. The effect size of smoking on methylation at this unique site is so large 
(>20% difference in DNA methylation between exposed and unexposed) that it is detectable 
even in low powered studies of small sample size. Methylation profiles have also been shown to 
be disrupted in children exposed to maternal smoking in utero 93, 103-104. Furthermore, 
methylation measures at this site have been used to identify nascent smokers 94. 
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The majority of studies conducted to date have been in European-ancestry populations but 
methylation differences appear to be very similar in South Asian and African American 
populations 99-100, 105. As well as being a biomarker of smoking exposure, DNA methylation has 
also been shown to predict disease outcomes: F2RL3 methylation is strongly associated with 
mortality 106, and AHRR methylation may be associated with subclinical atherosclerosis 107. 
 One of the major challenges in methylation studies is difficulty in inferring causal 
relationships. On a genome-wide scale, smoking-associated methylation changes can either be 
consequences of smoking, or predispose to smoking behavior. Further complications are caused 
by the dynamic nature of DNA methylation. Methylation at a given CpG site may reverse 
quickly after smoking cessation, others may reverse slowly, while some may be irreversible. 
DNA methylation as a tool to assess smoking status and history: 
Reliable assessment of smoking behavior and smoking history can be challenging, especially in 
higher risk settings where accurate quantification is most needed and where self-report is often 
least reliable. Examples of such groups include pregnant women who under report smoking 
during pregnancy when they know they are expected to reduce or quit tobacco use 108 or 
adolescents 109. Cotinine or exhaled carbon monoxide levels can be used to detect recent 
smoking but are generally only able to detect smoking exposure within hours or a few days 110-
113.   The concept of using DNA methylation as an archive of historical exposure has been 
mooted 114 and has been used to distinguish between never, former, and current smokers in 
recent studies 100, 115. 
DNA methylation and NMR: 
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A recent genome-wide association study of NMR in three Finnish cohorts reported 719 
significantly associated SNPs on chromosome 19q13, surrounding CYP2A6 32. The authors 
postulated that other gene regulatory mechanisms, including DNA methylation, may influence 
NMR. They interrogated the genome-wide significant SNPs to test whether they are associated 
with DNA methylation levels, i.e. are methylation quantitative trait loci (meQTLs). Methylation 
values of 16 CpG sites on 19q13 were found to be associated with genotypes at the genome-wide 
significant SNPs. Further, causal inference testing demonstrated that methylation levels at one 
CpG site tagged by cg08551532 (in DLL3, ~1.3 Mbp proximal to CYP2A6) mediated the effect 
of some of the SNPs on NMR.  
DNA methylation as a tool to evaluate smoking cessation: 
In addition to being associated with smoking per se, several CpG sites, including those at F2RL3, 
GPR15, LRRN3 and AHRR, are sensitive to cumulative smoking exposure and to cessation, with 
methylation levels reverting towards unexposed levels over time 95-96, 116. A cross-sectional study 
of over 3500 individuals reported that F2RL3 methylation decreased with smoking up to a 
maximum exposure of approximately 40 pack years. In former smokers, methylation was shown 
to increase with time since cessation until approximately 20-25 years after quitting, at which 
time methylation levels in former and never smoker were almost indistinguishable 116. AHRR 
findings are similar, with methylation levels in smokers gradually approaching levels of never 
smokers over a period of approximately 25 years 96. At other loci, the reversion of methylation 
patterns following cessation appears to be more rapid with some loci being indistinguishable 
between former and never smokers within 3 months 101.  
Although there is undoubtedly still work to be done to better define and characterize 
DNA methylation patterns in response to smoking behavior and cessation, this feature is of 
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particular interest to those interested in smoking cessation strategies. In this context DNA 
methylation may provide a useful tool to measure treatment efficacy, for example by using this 
biological measure rather than self-report which may be subject to bias. Because smoking 
cessation trials measure outcomes in weeks or months, such methylation changes would need to 
take place on a comparable time scale to be informative.  
 Given the sensitive and specific response of the peripheral blood methylation signature to 
exposure to tobacco smoke, there is great potential for application in the context of smoking 
cessation strategies. Two immediate examples of how this information could enhance existing 
studies are providing a refined measure of smoking behaviors (duration and heaviness of 
smoking) and predicting historical smoking behavior in the absence of self-reported data. Given 
the substantial effect sizes seen in DNA methylation in response to tobacco smoke, it is likely 
that this measure may be useful even in small sample sizes. DNA methylation patterns can vary 
between tissue and cell types and while it is certainly clear that blood methylation patterns reflect 
smoking behaviors, there is good evidence that patterns are similar in other accessible samples 
including buccal cells sampled from saliva 117. Furthermore, cheaper site specific methods are 
being developed meaning this type of measurement will be readily accessible for those 
considering using epigenetics to measure smoking exposure and monitor smoking cessation. 
 
5. Summary/Conclusions  
 This review has highlighted the value of collecting and generating data from biosamples 
from clinical smoking cessation treatment trials. First, evidence is accumulating that smokers' 
genotypes measured from DNA have utility for predicting not only risk of nicotine dependence 
and heavy smoking, but also cessation success under different treatments. The necessary DNA 
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can be extracted from blood, buccal swabs, or saliva for example, as discussed further in the 
companion paper Chen et al. Nicotine metabolism can be represented by genotypes and also by 
metabolite measurements in blood, plasma, or urine; such biomarkers of metabolism are proving 
informative for smoking cessation and treatment outcomes. Epigenetic studies in smokers, 
especially DNA methylation as a marker of smoking and cessation, constitute another exciting 
area of current investigation that is enabled by biosample collection.  
 Our review of genetic findings focused on the two most well-established genes that have 
been associated with nicotine dependence and smoking behaviors: CHRNA5 and CYP2A6. Both 
these genes also show strong evidence for involvement in response to pharmacologic smoking 
cessation treatment. Our goal here was to highlight the strongest results in the expectation that 
eventually, multiple findings with strong evidence will be available to inform personalized 
treatment.  Genomics implementation is a growing area of research focused on optimizing the 
integration of genomic findings into community and clinical settings; such research will ensure 
that basic science findings on established genetic variants (e.g., CHRNA5) are used to motivate 
smoking cessation and personalize treatment.  
 Limitations of the results reviewed here also highlight emerging opportunities. For 
example, many of these findings need to be investigated in other populations beyond those of 
European ancestry. Also, single SNPs discovered by GWAS tend to have modest effects on the 
smoking traits typically available in large consortium collaborations; this is due in part to the 
polygenic nature of behavioral traits and also the noise inherent in coarse measures such as 
cigarettes per day. Therefore it is important to move beyond individual SNP effect sizes, for 
example using polygenic risk scores. Also, other study designs that utilize more refined 
phenotypes can complement large efforts based on broader, more readily assessed phenotypes. 
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 Ultimately, clinical use of genomic testing to personalize smoking cessation treatment 
will also require establishing both clinical validity and also clinical utility, with development of 
laboratory diagnostic tests approved for specific contexts of care 118. These needs signal 
opportunities for researchers in smoking cessation and in genetics to work together on new 
genetic and epigenetic investigations. Much of the prior progress in identifying and validating 
genetic effects on nicotine dependence and smoking quantity came from collaborative 
consortium efforts. Similarly, as stated in the Introduction, we can tackle the genetics of smoking 
cessation and treatment through concerted, collaborative efforts. While literature-based meta-
analyses and systematic reviews offer one way to combine evidence across multiple studies 119,  
they are subject to heterogeneity across studies due to differences in ascertainment, phenotype 
definitions, and the statistical models tested and reported.  Greater power and accuracy is 
achieved through de novo, collaborative meta-analyses in which the primary investigators work 
together to reduce heterogeneity by harmonizing phenotypes and applying consistent statistical 
models to re-analyze data, prior to meta-analysis. This collaborative approach has been 
successful for smoking quantity 16, 40-43, 63 and has begun to be applied for cessation and treatment 
50. Data can be further optimized when studies communicate early in the study design phase and 
agree to use standardized phenotypic measures, such as those described in the PhenX Toolkit 120. 
Collaborations among experts from many domains - clinical, pharmacological, epidemiological, 
genetic, statistical, and more - will enable new insights into the biological underpinnings of 
smoking cessation treatment efficacy, and cessation success.  
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Table 1.  Glossary 
Term Definition 
Allele A particular DNA sequence or state possible at a genetic locus. 
Biomarker  A characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention. A biomarker 
that is intended to substitute for a clinical endpoint may be referred 
to as a "surrogate endpoint."  27.  
CAP College of American Pathologists: provides CAP accreditation 
programs for laboratories. 
CLIA Clinical Laboratory Improvements Amendments: United States 
federal regulatory standards for clinical laboratory testing. CLIA-
certification  
CNV Copy number variant: a genetic variant in which a particular stretch 
of DNA occurs with variable numbers of copies.  
DNA 
Sequencing 
The laboratory and analytical processes to determine the nucleotide 
sequence of a portion or all of a genome. 
Epigenetics Non-genetic sequence modifications of the DNA including DNA 
methylation, histone modifications, and miRNAs. Epigenetic processes 
regulate transcription and expression of genes. 
GWAS Genome-wide association study: a method for identifying genetic 
variants associated with a disease or quantitative trait by genotyping 
and analyzing a large number of variants across the genomes of 
multiple individuals who vary in their disease status or trait values. 
QTL Quantitative Trait Locus. A genetic variant that is associated with 
differential levels of a quantitative trait. Specific types include 
expression QTLs (eQTLs) associated with differences in gene 
expression levels and methylation QTLs (meQTLs) associated with 
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differences in gene methylation levels. 
SNP Single nucleotide polymorphism: a genetic variant occurring at a 
specific nucleotide in the DNA sequence.   
SNV Single nucleotide variant: similar to a SNP, but typically used when 
the variant may be of lower frequency (rarer). 
 
 
 
 
 
Table 2. Overview of key genetic associations cited in this review, between CHRNA5 and CYP2A6 genotypes and 
traits relevant for smoking and smoking cessation. 
Gene  Associated traits/outcomes 
CHRNA5 
 
GWAS-significant (p < 5E-08): 
Nicotine dependence38-39  
Smoking heaviness / cigarettes-per-day16, 38-43  
Biomarkers of smoking (cotinine levels29-30, carbon monoxide levels18) 
Lung cancer38, 44-45 
Chronic Obstructive Pulmonary Disease (COPD)46-47 
 
Other: 
Difficulty quitting in pregnant smokers48 
Delayed smoking cessation and earlier lung cancer diagnosis in smokers 14 
Differential response to pharmacological cessation treatment in some clinical trials49-50 
 
CYP2A6 
 
GWAS-significant (p < 5E-08): 
Smoking heaviness / cigarettes-per-day16, 40, 51 
Biomarker of nicotine metabolism: the Nicotine Metabolism Ratio (NMR)32-34, 52  
 
Other: 
Genotype-based biomarker of CYP2A6 enzyme activity 53 
Response to extended-duration transdermal nicotine therapy 54 
Response to pharmacologic smoking cessation treatment 55 
 
